Last reviewed · How we verify
Zepbound
At a glance
| Generic name | Zepbound |
|---|---|
| Also known as | Tirzepatide |
| Sponsor | The University of Texas Medical Branch, Galveston |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. ZEPBOUND is contraindicated in patients wi
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Dyspepsia
- Injection site reactions
- Fatigue
- Hypersensitivity reactions
- Eructation
- Hair loss
- Gastroesophageal reflux disease
Key clinical trials
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (PHASE2)
- Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (PHASE2)
- Tirzepatide to Slow Biological Aging (PHASE2)
- GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial (PHASE2, PHASE3)
- Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors (PHASE1)
- Tirzepatide Weight Loss for MRD+ Early Breast Cancer (PHASE2)
- GLP-1 Medicines and Mental Health Changes (NA)
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |